ArticleBMC surgery2025
Robotic laparoendoscopic single-site surgery by da Vinci Xi system in gynecology: a retrospective series of 721 cases.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical application and early experience of da Vinci Xi robotic single-site laparoscopic gynecologic surgery in mainland China: early experience from a retrospective consecutive cohort of 221 cases.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe main characteristics of the robotic surgical system include high-definition three-dimensional imaging, flexible and stable instruments, and an ergonomic console design. Incorporating robotic systems with laparoendoscopic single-site surgery (LESS) represents a promising concept to restore the operational triangulation, enhance surgical dexterity and precision, and reduce surgeons' fatigue, thereby improving surgical safety and efficacy. The objective of this study was to prove the feasibility, safety and efficacy of robotic LESS (R-LESS) using the da Vinci Xi surgical system in gynecology.
methodsThis was a retrospective study conducted at a tertiary hospital. We reviewed and descriptively analyzed patients' demographics and perioperative outcomes of all benign and malignant R-LESS procedures performed at West China Second University Hospital between April 28, 2021 and September 30, 2023.
resultsA total of 721 patients underwent R-LESS during the study period. In the 400 benign cases, the median operative time was 145.0 (115.0, 180.8) minutes with 45.0 (20.0, 60.0) mL blood loss. Two cases (0.5%) required an additional port, and 1 (0.3%) converted to laparotomy. The intraoperative complication rate was 1.0%. These patients were discharged at a median length of 4.0 (3.0, 5.0) days postoperatively, and the mean pain score at 24 h after surgery was 2.0 ± 0.8. The postoperative complication rate within 3 months was 2.3%. In the 321 malignant cases, the median operative time was 218.0 (170.0, 282.0) minutes with blood loss of 50.0 (50.0, 100.0) mL. The intraoperative complication and conversion rates were 2.8% and 1.9%, respectively.The median hospital stay was 5.0 (4.0, 6.0) days and the pain assessment at 24 h postoperatively was 2.0 ± 0.7. The postoperative complication rate within 3 months was 13.1%.
conclusionsR-LESS using the da Vinci Xi system is feasible and safe in performing various gynecologic procedures, especially complex cases, where the surgical challenges of LESS are significantly mitigated with robotic assistance. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.